论文部分内容阅读
目的:分析孟鲁司特治疗儿童过敏性紫癜的临床疗效。方法:选取我院2015年7月-2016年12月收治的78例儿童过敏性紫癜患者,按照入院顺序的前后性将所有患儿分为治疗组(n=39)和对照组(n=39)。对照组采用常规西医治疗,治疗组在对照组的基础上采用孟鲁司特治疗,对比两组患者的临床治疗效果。结果:治疗组的治愈率为21例(53.85%),好转率为16例(41.03%),治疗总康复率为37例(94.87%),明显优于对照组的治愈率18例(46.15%),好转率14例(35.90%)以及治疗总康复率32例(82.05%)(P<0.05)。结论:对过敏性紫癜患儿进行孟鲁司特治疗能够有效改善患儿的临床症状,提高治疗效率,值得临床推广。
Objective: To analyze the clinical efficacy of montelukast in the treatment of Henoch-Schonlein purpura in children. Methods: A total of 78 children with Henoch-Schonlein purpura were enrolled in our hospital from July 2015 to December 2016. All patients were divided into treatment group (n = 39) and control group (n = 39) according to the order of admission ). The control group was treated with conventional western medicine. The treatment group was treated with montelukast on the basis of the control group, and the clinical treatment effect was compared between the two groups. Results: The cure rate of treatment group was 21 cases (53.85%), the improvement rate was 16 cases (41.03%), the total recovery rate was 37 cases (94.87%), which was significantly better than that of the control group (18 cases, 46.15% ), Improvement rate of 14 cases (35.90%) and treatment of the total recovery rate of 32 cases (82.05%) (P <0.05). Conclusion: The montelukast treatment of children with Henoch-Schonlein purpura can effectively improve the clinical symptoms of children and improve the treatment efficiency, which is worthy of clinical promotion.